Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.790
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
1.780
-0.010 (-0.56%)
After-hours: Apr 2, 2026, 7:58 PM EDT
Ocugen Revenue
In the year 2025, Ocugen had annual revenue of $4.41M with 8.83% growth. Ocugen had revenue of $-193.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$4.41M
Revenue Growth
+8.83%
P/S Ratio
137.06
Revenue / Employee
$38,043
Employees
116
Market Cap
604.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.41M | 358.00K | 8.83% |
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| Gyre Therapeutics | 116.59M |
| Crescent Biopharma | 10.84M |
| Aclaris Therapeutics | 7.83M |
| Prime Medicine | 4.63M |
| ProKidney | 893.00K |
| Allogene Therapeutics | 22.00K |
OCGN News
- 2 days ago - Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - GlobeNewsWire
- 9 days ago - Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript - Seeking Alpha
- 9 days ago - Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Benzinga
- 10 days ago - Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 11 days ago - Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - GlobeNewsWire